INOZYME PHARMA, INC.

Analyst Reco. Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
4.65 ^USD	+0.22%		0.00%	+9.15%

05-07	Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Transcript : Inozyme Pharma, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Upgrades Inozyme Pharma to Buy From Hold, Adjusts Price Target to $6 From $4.50	23/03/23	MT
Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating	11/11/22	MT
Wedbush Adjusts Inozyme Pharma Price Target to $20 From $23, Maintains Outperform Rating	20/07/22	MT
Jefferies & Co. Initiates Inozyme Pharma, Inc at Hold, Price Target Set at $5	26/05/22	MT
HC Wainwright Lowers Inozyme Pharma's Price Target to $20 From $33, Maintains Buy Rating	11/05/22	MT
Wedbush Adjusts Price Target for Inozyme Pharma to $23 From $25, Maintains Outperform Rating	10/05/22	MT
Wedbush Adjusts Inozyme Pharma's Price Target to $25 From $35, Citing Cost of Capital; Outperform Rating Kept	16/03/22	MT
HC Wainwright Starts Inozyme Pharma at Buy With $33 Price Target	07/02/22	MT
Needham Starts Inozyme Pharma at Buy With $23 Price Target	29/11/21	MT
Wedbush Trims Inozyme Pharma's Price Target to $35 From $37; Outperform Rating Kept	10/11/21	MT
INOZYME PHARMA : Wedbush Adjusts Price Target on Inozyme Pharma to $37 From $35, Keeps Outperform Rating	13/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer